<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Irinotecan and infusional <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi>-based chemotherapy (FOLFIRI) plus bevacizumab (FOLFIRI-B) is one of the most effective treatments of advanced <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>However, this schedule is regarded more extensively as first-line therapy and its efficacy has not been proven in phase III randomised trials in <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>-pretreated patients </plain></SENT>
<SENT sid="2" pm="."><plain>We have performed a systematic review through PubMed and EMBASE, including <z:hpo ids='HP_0000001'>all</z:hpo> prospective and retrospective publications exploring the efficacy of FOLFIRI-B as second-line chemotherapy in advanced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients pretreated with <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> and not with B </plain></SENT>
<SENT sid="3" pm="."><plain>Pooled estimates of the response rates (RR), weighted medians of progression-free survival (PFS), and overall survival (OS) from <z:hpo ids='HP_0000001'>all</z:hpo> FOLFIRI-B-containing arms were calculated </plain></SENT>
<SENT sid="4" pm="."><plain>A total of 11 studies (one randomised phase II trial, two phase II trials, two observational studies, two prospective non-randomised collections, and four retrospective case series) were retrieved giving a total of 435 patients </plain></SENT>
<SENT sid="5" pm="."><plain>Overall, the pooled RR (n = 11 publications) was 26 % </plain></SENT>
<SENT sid="6" pm="."><plain>Median PFS and OS (n = 11 and 10 publications, respectively) were 8.3 and 17.2 months </plain></SENT>
<SENT sid="7" pm="."><plain>FOLFIRI-B is a reasonable and effective option for stage IV <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> pretreated with <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> and not exposed to B during first-line treatment </plain></SENT>
<SENT sid="8" pm="."><plain>Its activity seems better than historical FOLFIRI-based second-line trials </plain></SENT>
</text></document>